Back to top

gene-editing: Archive

Zacks Equity Research

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

VRTXPositive Net Change CPRXPositive Net Change CRSPPositive Net Change CSTLNegative Net Change